Midbrain dopaminergic neurons play a critical role in multiple brain functions, and abnormal signaling through dopaminergic pathways has been implicated in several major neurologic and psychiatric disorders. One well-studied target for the actions of dopamine is DARPP32. In the densely dopamine- and glutamate-innervated rat caudate-putamen, DARPP32 is expressed in medium-sized spiny neurons (Ouimet and Greengard, 1990 Mouse monoclonal antibody raised against a full length recombinant PPP1R1B.
Applications: IF Reactive species: Human
"Abstract: The dorsal striatum forms a central node of the basal ganglia interconnecting the neocortex and thalamus with circuits modulating mood and movement. Striatal projection neurons (SPNs) include relatively intermixed populations expressing D1-type or D2-type dopamine receptors (dSPNs and iSPNs) that give rise to the direct (D1) and indirect (D2) output systems of the basal ganglia. Overlaid on this organization is a compartmental organization, in which a labyrinthine system of striosomes made up of sequestered SPNs is embedded within the larger striatal matrix. Striosomal SPNs also include D1-SPNs and D2-SPNs, but they can be distinguished from matrix SPNs by many neurochemical markers. In the rodent striatum the key signaling molecule, DARPP-32, is a exception to these compartmental expression patterns, thought to befit its functions through opposite actions in both D1- and D2-expressing SPNs. We demonstrate here, however, that in the dorsal human striatum, DARPP-32 is concentrated in the neuropil and SPNs of striosomes, especially in the caudate nucleus and dorsomedial putamen, relative to the matrix neuropil in these regions. The generally DARPP-32-poor matrix contains scattered DARPP-32-positive cells. DARPP-32 cell bodies in both compartments proved negative for conventional intraneuronal markers." Article snippet: DARPP-32 (Creative Diagnostics, New York, USA; Cat. No. CABT22918MH, RRID: AB_2472670): This mouse monoclonal antibody was raised against a full-length recombinant PPP1R1B (manufacturer’s product sheet).
Figure 1. Photomicrographs showing the distinctive difference between DARPP-32 staining in human and rat striatum
Background
Protein phosphatase 1 regulatory subunit 1B (PPP1R1B), also known as dopamine- and cAMP-regulated neuronal phosphoprotein (DARPP-32), is a highly abundant and well-studied neuronal protein. This protein is primarily expressed in medium-spiny neurons of the striatum, a brain region that is critical for motor control, reward processing, and various cognitive functions.
DARPP-32 plays a central role in integrating dopaminergic and glutamatergic neurotransmission in the striatum. When phosphorylated, DARPP-32 acts as a potent inhibitor of protein phosphatase-1 (PP1), a ubiquitous serine/threonine phosphatase. This inhibition of PP1 allows for the propagation of various signaling cascades downstream of dopamine and glutamate receptors, affecting neuronal excitability, synaptic plasticity, and gene expression. The phosphorylation state of DARPP-32 is tightly regulated by a balance of kinase and phosphatase activities. Dopamine D1 receptor stimulation leads to DARPP-32 phosphorylation, while glutamatergic NMDA receptor activation promotes its dephosphorylation. This makes DARPP-32 a critical node in the integration of these two major neurotransmitter systems within striatal neurons.
Figure 1. Central role of the DARPP-32/PP-1 pathway in signal transduction in medium spiny neurons. (Source: Greengard, P. et al., 1999)
DARPP-32 has emerged as a key player in the pathogenesis of diverse neurological and psychiatric disorders. Dysregulation of DARPP-32 has been implicated in the etiology of conditions including Parkinson's disease, schizophrenia, and addiction, underscoring its significance in central nervous system dysfunction. Furthermore, the aberrant expression and activity of the PPP1R1B gene, encoding DARPP-32, have been observed in specific cancer types. In these malignancies, the overexpression of DARPP-32 and its isoforms may exert detrimental effects by promoting disease progression and conferring resistance to therapeutic interventions. The multifaceted involvement of DARPP-32 in both neurological and neoplastic contexts highlights its potential as a promising target for therapeutic interventions and underscores the need for further investigations to unravel the underlying molecular mechanisms and clinical implications associated with its dysregulation in these complex disorders.
Q: How we reconstitute the blocking peptide sent with this antibody?
A: You could reconstitute the peptide with DD water.
Customer Reviews
My Review for Anti-PPP1R1B monoclonal antibody, clone 4H22
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
References
Darpp-32 and t-Darpp protein products of PPP1R1B: Old dogs with new tricks
The PPP1R1B gene is located on chromosome 17q12 (39,626,208-39,636,626[GRCh38/hg38]), which codes for multiple transcripts and two experimentally-documented proteins Darpp-32 and t-Darpp. Darpp-32 (Dopamine and cAMP Regulated Phosphoprotein), discovered in the early 1980s, is a protein whose phosphorylation is upregulated in response to cAMP in dopamine-responsive tissues in the brain. It's phosphorylation profile modulates its ability to bind and inhibit Protein Phosphatase 1 activity, which, in turn, controls the activity of hundreds of phosphorylated proteins. PPP1R1B knockout mice exhibit subtle learning defects. In 2002, the second protein product of PPP1R1B was discovered in gastric cancers: t-Darpp (truncated Darpp-32). The start codon of t-Darpp is amino acid residue 37 of Darpp-32 and it lacks the domain responsible for modulating Protein Phosphatase 1. Aside from gastric cancers, t-Darpp and/or Darpp-32 is overexpressed in tumor cells from breast, colon, esophagus, lung and prostate tissues. More than one research team has demonstrated that these proteins, through mechanisms that to date remain cloudy, activate AKT, a protein whose phosphorylation leads to cell survival and blocks apoptosis. Furthermore, in Her2 positive breast cancers (an aggressive form of breast cancer), t-Darpp/Darpp-32 overexpression causes resistance to the frequently-administered anti-Her2 drug, trastuzumab (Herceptin), likely through AKT activation. Here we briefly describe how Darpp-32 and t-Darpp were discovered and report on the current state of knowledge of their involvement in cancers. We present a case for the development of an anti-t-Darpp therapeutic agent and outline the unique challenges this endeavor will likely encounter.
An association study between PPP1R1B gene and schizophrenia in the Chinese population
Progress in Neuro-Psychopharmacology and Biological Psychiatry
Authors: Hu, J. X., Yu, L., Shi, Y. Y., Zhao, X. Z., Meng, J. W., He, G., He, L.
Schizophrenia has been linked with dysfunctions of glutamatergic, dopaminergic, and serotonergic neurotransmission. Dopamine- and cAMP-regulated phosphoprotein of relative molecular mass 32 kDa (DARPP-32), encoded by PPP1R1B (protein phosphatase 1, regulatory/inhibitor subunit 1B) gene, is enriched in neostriatal medium spiny neurons. It plays a key regulator role in dopaminergic and glutamatergic signaling pathways. The combined evidence from reduced DARPP-32 expression in the dorsolateral prefrontal cortex (DLPFC) in schizophrenic patients and from abnormalities in mice with a genetic deletion of DARPP-32 or with point mutations in phosphorylation sites of DARPP-32 suggested that it would be worthwhile to investigate the association between DARPP-32 and schizophrenia. In the present study, we genotyped five single nucleotide polymorphisms (SNPs) in the PPP1R1B gene and conducted a case-control study involving 520 schizophrenic patients and 386 healthy subjects drawn from the Chinese population. No allelic, genotypic or haplotypic association was found. However, our results do not preclude the possibility that the PPP1R1B is a susceptibility gene for schizophrenia in the Chinese population, since, as a central molecular switch, PPP1R1B may contribute to schizophrenia by interacting with other genes. Further functional analysis and genetic association studies are needed to determine the potential roles of PPP1R1B and other related genes in the pathophysiology of schizophrenia.
COA
Publication 
Figure 1. Central role of the DARPP-32/PP-1 pathway in signal transduction in medium spiny neurons.
Loading ......
